Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT01083732
- Locations
- 🇹🇭
Boehringer Ingelheim Investigational Site, Khon Kaen, Thailand
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 241
- Registration Number
- NCT01084005
- Locations
- 🇩🇰
1218.63.45007 Boehringer Ingelheim Investigational Site, Aalborg, Denmark
🇩🇰1218.63.45003 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark
🇩🇰1218.63.45001 Boehringer Ingelheim Investigational Site, Birkerød, Denmark
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 126
- Registration Number
- NCT01072396
- Locations
- 🇺🇸
205.440.1002 Boehringer Ingelheim Investigational Site, Torrance, California, United States
🇺🇸205.440.1018 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States
🇺🇸205.440.1015 Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States
Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice
- Conditions
- Parkinson's Disease
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1814
- Registration Number
- NCT01061567
- Locations
- 🇪🇪
Boehringer Ingelheim Investigational Site 115, Järvamaa, Estonia
🇦🇹Boehringer Ingelheim Investigational Site 2, Bad Radkersburg, Austria
🇦🇹Boehringer Ingelheim Investigational Site 19, Graz, Austria
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1452
- Registration Number
- NCT01050062
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 234, Akashi, Japan
🇯🇵Boehringer Ingelheim Investigational Site 237, Amagasaki, Japan
🇯🇵Boehringer Ingelheim Investigational Site 141, Chigasaki, Japan
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 157
- Registration Number
- NCT01040793
- Locations
- 🇧🇪
1222.38.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇦🇹1222.38.4381 Boehringer Ingelheim Investigational Site, Leoben, Austria
🇧🇪1222.38.32004 Boehringer Ingelheim Investigational Site, Brussel, Belgium
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo (for Tiotropium)
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 108
- Registration Number
- NCT01040689
- Locations
- 🇧🇪
1222.39.32003 Boehringer Ingelheim Investigational Site, Genk, Belgium
🇩🇰1222.39.45002 Boehringer Ingelheim Investigational Site, Odense C, Denmark
🇩🇰1222.39.45001 Boehringer Ingelheim Investigational Site, Hvidovre, Denmark
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 122
- Registration Number
- NCT01040728
- Locations
- 🇳🇴
1222.40.47002 Boehringer Ingelheim Investigational Site, Drammen, Norway
🇳🇱1222.40.31002 Boehringer Ingelheim Investigational Site, Eindhoven, Netherlands
🇳🇱1222.40.31003 Boehringer Ingelheim Investigational Site, Breda, Netherlands
Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 233
- Registration Number
- NCT01040403
- Locations
- 🇩🇪
1237.18.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇨🇦1237.18.02003 Boehringer Ingelheim Investigational Site, Point Claire, Quebec, Canada
🇸🇪1237.18.46003 Boehringer Ingelheim Investigational Site, Boden, Sweden
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 151
- Registration Number
- NCT01040130
- Locations
- 🇦🇺
1222.37.6171 Boehringer Ingelheim Investigational Site, Daw Park, South Australia, Australia
🇦🇹1222.37.4371 Boehringer Ingelheim Investigational Site, Gänserndorf, Austria
🇦🇺1222.37.6172 Boehringer Ingelheim Investigational Site, Melbourne, Victoria, Australia